$FBLG

FibroBiologics, Inc. (FBLG) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On September 15, 2026, FibroBiologics, Inc. (the “Company”) entered into a securities purchase agreement (the “SPA”) with Hamid Khoja, Ph.D., the Company’s Chief Scientific Officer (the “Purchaser”), relating to the issuance a

FibroBiologics (FBLG) received a U.S. patent for its fibroblast-based wound healing therapy. Preclinical studies showed faster healing, including in diabetic models. The stock is down 9.74% to $1.76.

FibroBiologics (FBLG) shipped a new batch of its experimental drug CYWC628 to Australia for a clinical trial on diabetic foot ulcers. The Phase 1/2 study evaluates safety, tolerability, and efficacy of the treatment. The company expects to report interim data in late 2026, with preclinical data suggesting potential for accelerated wound healing. FibroBiologics focuses on treatments for chronic diseases using fibroblast cells.

FibroBiologics (Nasdaq: FBLG) reported that its preclinical study showed cartilage repair in degenerative joints within four weeks of a single injection of chondrocyte spheroids. The company claims the therapy could offer a less invasive, lower-cost alternative to joint replacement, with a rapid four-day manufacturing process. FibroBiologics holds over 270 patents in various clinical pathways, including orthopedics.

FibroBiologics, Inc. (FBLG) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 FibroBiologics Appoints Leigh Steinberg to Board of Directors Legendary Sports Agent, Attorney, and Longtime Advocate for Human Longevity and Brain Health Joins Board HOUSTON, August 24, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a c

FibroBiologics (Nasdaq: FBLG) reported preclinical results for fibroblast-spheroid-derived chondrocyte spheroids (FSdCS) in animals with induced joint defects. According to the company, a single injection led to cartilage repair within four weeks. The company says FSdCS manufacturing takes four days and could support a lower-cost, scalable biologic alternative to joint replacement.

FibroBiologics (Nasdaq: FBLG) reported Q2 2026 results and said it dosed the first patients in its Phase 1/2 trial of CYWC628 for diabetic foot ulcers. It completed cGMP manufacturing of three CYWC628 batches. The company raised $9.0 million via private placement and $3.0 million in a public offering. Q2 net loss was about $4.1 million, with cash of about $3.5 million at June 30, 2026.

FibroBiologics, Inc. (FBLG) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K false 0001958777 0001958777 2026-07-02 2026-07-02 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 02,

FibroBiologics, Inc. (FBLG) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 5 fblg-ex10_1.htm EX-10.1 EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “ Agreement ”) is dated as of June 25, 2026, between FibroBiologics, Inc., a Delaware corporation (the “ Company ”), and each purchaser identified on the

FibroBiologics, Inc. (FBLG) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 fblg-ex10_1.htm EX-10.1 EX-10.1 Exhibit 10.1 FIBROBIOLOGICS, INC. 2026 EQUITY AND INCENTIVE COMPENSATION PLAN 1. Purpose . The purpose of this Plan is to permit award grants to Participants and to provide to such persons incentives and rewards for service and/or perform